Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Uveal Melanoma 1Neoplasm Metastasis 1Metastatic gpNMB Expressing Triple Negative Breast Cancer 1Melanoma 1

Interventions

Nivolumab 2Cyclophosphamide 2tislelizumab 1spartalizumab 1pembrolizumab 1montanide ISA 51 1glembatumumab vedotin 1fludarabine phosphate 1entinostat 1cemiplimab 1Toll-Like Receptor 1 1Surveys and Questionnaires 1Specimen Handling 1Rose Bengal 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Interleukin-13 1Focus Groups 1Fluorodeoxyglucose F18 1Cryosurgery 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × glembatumumab vedotin × Breast × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡